解析AI监管难题:深度学习质检在欧盟医疗设备合规中的挑战
Navigating the EU AI Act: Foreseeable Challenges in Qualifying Deep Learning-Based Automated Inspections of Class III Medical Devices
- 对比EU AI Act与MDR/QSR,分析风险管控差异
- 指出缺陷数据少导致验证难、统计显著性不足
- 适合医疗器械企业与AI合规团队参考
随着深度学习技术发展,基于DL的自动化视觉检测在Ⅲ类医疗设备质量保证中展现出巨大潜力,可减少人为错误。然而,此类AI系统在欧盟《人工智能法案》(EU AI Act)下被归为高风险,其义务范围和深度与现有MDR及美国FDA QSR框架存在差异,带来新的监管复杂性。本文针对静态模型的DL自动化检测系统,开展技术层面评估,探讨制造商在现有合规体系中可能面临的挑战,包括风险管理体系差异、数据治理要求、模型验证方法、可解释性标准以及部署后监测责任等。同时讨论潜在实施策略,揭示数据留存负担、全球合规影响及缺陷样本有限导致验证难以达到统计显著性的实际困难。需注意:本文仅为技术视角,不构成法律或监管建议。
原文摘要 · Abstract (English)
As deep learning (DL) technologies advance, their application in automated visual inspection for Class III medical devices offers significant potential to enhance quality assurance and reduce human error. However, the adoption of such AI-based systems introduces new regulatory complexities-particularly under the EU Artificial Intelligence (AI) Act, which imposes high-risk system obligations that differ in scope and depth from established regulatory frameworks such as the Medical Device Regulation (MDR) and the U.S. FDA Quality System Regulation (QSR). This paper presents a high-level technical assessment of the foreseeable challenges that manufacturers are likely to encounter when qualifying DL-based automated inspections -- specifically static models -- within the existing medical device compliance landscape. It examines divergences in risk management principles, dataset governance, model validation, explainability requirements, and post-deployment monitoring obligations. The discussion also explores potential implementation strategies and highlights areas of uncertainty, including data retention burdens, global compliance implications, and the practical difficulties of achieving statistical significance in validation with limited defect data. Disclaimer: This paper presents a technical perspective and does not constitute legal or regulatory advice.
Thank you to arXiv for use of its open access interoperability. PaperDance 不是 arXiv 官方产品;中文卡片由大模型生成,请以原文为准。